Studies on Medicinally Interested Compounds

Not availabl

Optimization of thickness of Sb2Te3 thin film as back contact for CdTe thin film solar cells

Sb2Te3 thin films of different thickness ranging from 100 to 500 nm were prepd. on glass substrate by thermal evapn. method. The effects of thickness on structural, optical and elec. properties of thin films were studied. XRD revealed that grain size increases from 1.1nm to 98.7 nm with increase in film thickness. The internal strain and dislocation d. decreased with increase in film thickness. The optical band gap decreases from 1.3 to 0.9 eV with increase in film thickness. AFM images indicated cryst. nature of Sb2Te3. Surface roughness increased up to 400nm after which it decreased. The resistivity decreases with increase in thickness at room temp. ranging from 2.9×10-​3 to 1.35×10-​4 Ωcm. The work function and barrier height decreases as the film thickness increases from 5.45 to 5.05eV and barrier height from 0.3 to -​0.1eV. The results elucidate that Sb2Te3 back contact of 400 nm thickness is ideal and efficient to be used in CdTe solar cell

A cross sectional study of knowledge, attitude and practices related to fixed dose combinations use among clinicians and resident doctors at a tertiary care teaching hospital in India

Background: In the year 2016, Government of India had banned 350 fixed dose combinations (FDCs) for the safety and efficacy purpose. The present study was conducted to assess the knowledge, attitude and practices of the clinicians and residents about the use of FDCs at a tertiary care hospital.Methods: A questionnaire based study was conducted at a tertiary care hospital after getting approval from institutional ethics committee. A pre-validated questionnaire comprising of 30 items was distributed to 100 participants. The questionnaire focused on the prescribing behaviour, knowledge on therapeutic efficacy, advantages and limitations of FDC use, clinician perception regarding FDC use and the strategies to improve the awareness about the regulatory updates of the marketed drugs.Results: Total 52/100 clinicians responded. Out of these, 88% prescribed FDCs in their practice, 62% prescribed FDCs only after ensuring therapeutic efficacy and 50% prescribed WHO approved FDCs. 64% were aware of the recent ban on some FDCs by DCGI. Internet was the most common source of latest updates on the regulatory status of the drug, as stated by 55% clinicians. All clinicians agreed that efforts are needed to ensure that prescribers remain up to date about the post-marketing regulatory status of the drugs.Conclusions: Even though many clinicians prescribe FDCs regularly, they appreciated the step of banning some FDCs; however, the clinicians need to be trained to update themselves regularly. The source and relevance of these updates should be taught to the undergraduate students during their training period which can be reemphasized during post graduate training period

Učinak ricinoleične kiseline iz ricinusova ulja na proizvodna svojstva i hemato-biokemijski profil krava pasmine Kankrej u laktaciji

The aim of the present study was to evaluate the effects of dietary ricinoleic acid from castor oil on the milk yield, composition, fatty acid profile and haemato-biochemical profile in lactating Kankrej cows. Twenty lactating Kankrej cows were assigned to the following groups: control (CON), basal diet without any additive and treatment (RAS), basal diet with 2 g/animal/day of ricinoleic acid from castor oil. Dietary ricinoleic acid had no (P>0.05) effect on dry matter intake and feed efficiency. Milk yield (milk, 4% fat corrected milk and energy corrected milk) were not affected (P>0.05) by the feeding of ricinoleic acid. The milk composition showed no significant differences between the groups. A significantly (P0.05) in haemato-biochemical profile between the CON and RAS groups. It was concluded that supplementation of 2 g/animal/day ricinoleic acid from castor oil had no effect on milk yield, milk composition and haemato-biochemical profile. However, it increased the milk fat percentages of unsaturated fatty acids and polyunsaturated fatty acids, and decreased milk saturated fatty acids, without any adverse effect on the health status of the cows.Cilj istraživanja bio je procijeniti učinak ricinoleične kiseline iz ricinusova ulja na prinos mlijeka, kemijski sastav mlijeka, profil masnih kiselina u mlijeku te na hemato-biokemijski profil krava pasmine Kankrej u laktaciji. Ukupno 20 krava u laktaciji podijeljeno je u: kontrolnu skupinu (CON), skupinu koja je dobivala osnovnu hranu, bez dodataka i pokusnu skupinu (RAS), koja je dobivala osnovnu hranu i 2 g po životinji dnevno ricinoleične kiseline iz ricinusova ulja. Ricinoleična kiselina nije imala učinka (P>0,05) na unos suhe tvari i iskorištavanje hrane. Dodatak ricinoleične kiseline nije utjecao (P>0,05) na prinos mlijeka (mlijeko, obogaćeno mlijeko s 4 % masnoće i energijski obogaćeno mlijeko). Sastav mlijeka nije pokazao znakovite razlike među skupinama. Uočen je znakovito veći postotak C4:0, C6:0 i C8:0 u mlijeku u skupini RAS (P0,05) u hemato-biokemijskom profilu skupina CON i RAS. Zaključeno je da dodatak 2 g ricinoleične kiseline po životinji dnevno ne utječe na prinos i sastav mlijeka te hemato- biokemijski profil, međutim povećava postotak mliječne masti, nezasićenih masnih kiselina i višestruko nezasićenih masnih kiselina, a smanjuje postotak zasićenih masnih kiselina bez posljedica za zdravlje krava

A prospective study on causality, severity and preventability assessment of adverse drug reactions in a tertiary care hospital in India

Background: The present study was undertaken to evaluate the incidence and pattern of adverse drug reaction (ADRs), causality, severity and preventability of ADRs.Methods: Data was collected and analyzed with the information such as patients’ demographic details, associated co-morbid conditions and detailed drug related information gathered from ADR reporting forms. World Health Organization (WHO) scale was used for assessing causality, modified Hartwig scale was used for assessing severity and modified Schumock and Thorntons scale were used for assessing preventability of ADRs. Data was analyzed using descriptive statistics.Results: Total 154 ADRs were reported in a period of one year (August 2016- July 2017). Out of 154 ADRs analyzed, 120 (77.9%) were in adults, 33 (21.4%) pediatric and 01 (0.7%) in geriatric patients. The most common ADR recorded was cutaneous reactions (43.5%) and the most common causative class of drugs for the same was found to be antimicrobials (46.7%) followed by non-steroidal anti-inflammatory drugs (15.6%). Causality assessment scale indicated 68.8% ADRs possible and 24% ADRs as probable. Severity assessment revealed that 45.5 % were mild, 50.6% moderate and 3.9% ADRs severe. Preventability assessment showed 84.4% of the cases were probably non-preventable.Conclusions: In this study it was found that, most of the ADRs were of possible category with mild to moderate severity and majority being non-preventable. Antimicrobial drugs being the most common offending drug class causing ADRs. Strategies targeting appropriate and cautious use of this class of drugs may benefit in reducing the number of ADRs and therefore the cost involved in the treatment

Performance analysis of cow dung as an eco-friendly binder and additive material for sustainable moulding and casting

Abstract: In the present work, an attempt is made to partially replace the high cost silica sand with sustainable eco-friendly material, namely cow-dung. Practical utility of cow dung as a binding and additive material in foundries has been tested in the present work. Taguchi method is used to plan and conduct nine experiments with three replicates each. Pareto analysis of variance study is done to understand the practical significance of moulding sand variables namely percent of cow dung, percent of clay, percent of water, and degree of ramming on sand mould properties. The conflicting multiple objective functions (maximize: mould hardness, and minimize: collapsibility and gas evolution) are optimized by utilizing data envelopment analysis ranking (DEAR) method. The optimal parameter levels i.e. 6% of clay, 4% of water, 5% of cow-dung and 4 numbers of ramming strokes are obtained by applying hybrid Taguchi- DEAR method. These parameters yielded the best moulding properties i.e. mould hardness 55, gas evolution 5.9 ml/gm , and collapsibility 470 g/cm2. Thereafter, Lovejoy coupling made of aluminium is cast in the sand mould prepared with cow-dung and without cow-dung. The sand mould is prepared with the optimum set of parameters and the casting produced in the mould has been tested for its quality characteristics. The mechanical properties, surface finish, and microstructure of the casting made in sand mould with cow-dung are found to be better than that obtained with sand mould without cow-dung. The present research work is found to be more useful in foundries for sustainable production of good quality casting

Evaluation of prescribing pattern of drugs use in patients of coronary artery disease at a tertiary care hospital

Background: Coronary artery disease (CAD) is a major cause responsible for mortality more in younger age group than in elderly. Studies have reported underuse of four evidence based medicines namely aspirin, β-blockers, angiotensin-converting enzyme inhibitors (ACE-I) or angiotensin receptor blockers (ARB), and statins in patients with CAD, particularly in developing countries. Therefore, this study was planned to analyse the prescriptions of patients with CAD to determine the appropriateness of the prescriptions.Methods: After obtaining the Institutional ethics committee permission, a cross sectional observational study was conducted at a tertiary care hospital. Total 150 patients were enrolled from the outpatient department, wards and intensive care unit of medicine department. Total 150 patients’ prescriptions presenting with varied category of CAD were screened and analysed.Results: The most common categories of CAD encountered was ST segment elevated myocardial infarction (N=50, 33%) followed by chronic stable angina (N=29, 20%). Among the drugs prescribed, antiplatelet drugs were prescribed to 135 (90%), hypolipidemics to 134 (89%), nitrates to 114 (76%), beta blockers to 97 (65%), ACE inhibitors to 94 (64%), anticoagulants to 60 (40%) and miscellaneous drugs to 52 (35%), patients. Of 68 (45%) patients with type 2 diabetes mellitus, 15 (22%) were prescribed only metoprolol and others were given ACE-I or ARBs.Conclusions: Among four evidence based drugs, use of 3 drugs, antiplatelets, beta blockers and hypolipidemics was apparent in 90% of prescriptions. Use of ACE inhibitors and ARBs was observed in type 2 diabetic patients with CAD, reflecting rational prescribing behavior of clinicians

Gastrointestinal stromal tumour in Meckel's diverticulum

<p>Abstract</p> <p>Background</p> <p>Meckel's Diverticulum is the most commonly encountered congenital anomaly of the small intestine, occurring in approximately 2% of the population. Occasionally Meckel's diverticulum harbors neoplasms.</p> <p>Case presentation</p> <p>A 65 year old gentleman, presented with a pelvic mass. On exploratory laparotomy, it turned out to be gastrointestinal stromal tumour (GIST) arising from Meckel's diverticulum. Short history and review of literature are discussed.</p> <p>Conclusion</p> <p>Neoplasms occurring from Meckel's diverticulum, even though rare, should be considered as differential diagnosis of pelvic masses arising from bowel, wherever imaging modalities fail to give a definitive diagnosis.</p

A Phase 1/2 Study of Azacitidine, Venetoclax and Pevonedistat in Newly Diagnosed Secondary AML and in MDS or CMMLAfter Failure of Hypomethylating Agents

BACKGROUND: Pevonedistat is a first-in-class, small molecular inhibitor of NEDD8-activating enzyme that has clinical activity in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Preclinical data suggest synergy of pevonedistat with azacitidine and venetoclax. METHODS: This single-center, phase 1/2 study evaluated the combination of azacitidine, venetoclax and pevonedistat in older adults with newly diagnosed secondary AML or with MDS or chronic myelomonocytic leukemia (CMML) after failure of hypomethylating agents. Patients received azacitidine 75 mg/m FINDINGS: Forty patients were enrolled (32 with AML and 8 with MDS/CMML). In the AML cohort, the median age was 74 years (range 61-86 years), and 27 patients (84%) had at least one adverse risk cyto-molecular feature, including 15 (47%) with a TP53 mutation or MECOM rearrangement; seventeen patients (53%) had received prior therapy for a preceding myeloid disorder. The CR/CRi rate was 66% (CR 50%; CRi 16%), and the median overall survival (OS) was 8.1 months. In the MDS/CMML cohort, 7 patients (87%) were high or very high risk by the IPSS-R. The overall response rate was 75% (CR 13%; mCR with or without HI 50%; HI 13%). The most common grade 3-4 adverse events were infection in 16 patients (35%), febrile neutropenia in 10 patients (25%) and hypophosphatemia in 9 patients (23%). In an exploratory analysis, early upregulation of NOXA expression was observed, with subsequent decrease in MCL-1 and FLIP, findings consistent with preclinical mechanistic studies of pevonedistat. Upregulation of CD36 was observed, which may have contributed to therapeutic resistance. CONCLUSIONS: The triplet combination of azacitidine, venetoclax and pevonedistat shows encouraging activity in this very poor-risk population of patients with AML, MDS or CMML. Trial registration ClinicalTrials.gov (NCT03862157)

A Phase 1/2 Study of Azacitidine, Venetoclax and Pevonedistat in Newly Diagnosed Secondary AML and in MDS or CMML After Failure of Hypomethylating Agents

BACKGROUND: Pevonedistat is a first-in-class, small molecular inhibitor of NEDD8-activating enzyme that has clinical activity in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Preclinical data suggest synergy of pevonedistat with azacitidine and venetoclax. METHODS: This single-center, phase 1/2 study evaluated the combination of azacitidine, venetoclax and pevonedistat in older adults with newly diagnosed secondary AML or with MDS or chronic myelomonocytic leukemia (CMML) after failure of hypomethylating agents. Patients received azacitidine 75 mg/m FINDINGS: Forty patients were enrolled (32 with AML and 8 with MDS/CMML). In the AML cohort, the median age was 74 years (range 61-86 years), and 27 patients (84%) had at least one adverse risk cyto-molecular feature, including 15 (47%) with a TP53 mutation or MECOM rearrangement; seventeen patients (53%) had received prior therapy for a preceding myeloid disorder. The CR/CRi rate was 66% (CR 50%; CRi 16%), and the median overall survival (OS) was 8.1 months. In the MDS/CMML cohort, 7 patients (87%) were high or very high risk by the IPSS-R. The overall response rate was 75% (CR 13%; mCR with or without HI 50%; HI 13%). The most common grade 3-4 adverse events were infection in 16 patients (35%), febrile neutropenia in 10 patients (25%) and hypophosphatemia in 9 patients (23%). In an exploratory analysis, early upregulation of NOXA expression was observed, with subsequent decrease in MCL-1 and FLIP, findings consistent with preclinical mechanistic studies of pevonedistat. Upregulation of CD36 was observed, which may have contributed to therapeutic resistance. CONCLUSIONS: The triplet combination of azacitidine, venetoclax and pevonedistat shows encouraging activity in this very poor-risk population of patients with AML, MDS or CMML. Trial registration ClinicalTrials.gov (NCT03862157)